I-01 Noha Abdelgawad
Population pharmacokinetic modeling of rifampicin at standard and high doses in adults with tuberculous meningitis
Wednesday 10:00-11:30 |
I-07 Mounier Almett
Population Pharmacokinetic Modelling of Twice Daily 50mg Dolutegravir in Children with Tuberculosis and HIV during Rifampicin Co-administration
Wednesday 10:00-11:30 |
I-10 Arkadiusz Adamiszak
Antibiotic pharmacokinetic modelling versus antibiotic therapy optimisation and resistance reduction: Bibliometric analysis
Wednesday 10:00-11:30 |
I-13 Aurélie Barrail-Tran
Population pharmacokinetic modelling of dolutegravir, tenofovir and emtricitabine in non-human primates
Wednesday 10:00-11:30 |
I-19 Sandra Berja
Population PK analysis of chloroquine in a humanized mouse model of P.falciparum malaria
Wednesday 10:00-11:30 |
I-22 Jose Miguel Calderin Miranda
Pharmacokinetic analysis of pyrazinamide in a South African population with tuberculosis meningitis and HIV
Wednesday 10:00-11:30 |
I-25 Anan Chanruang
Population pharmacokinetics of dolutegravir co-administered with rifampicin in Thai people living with HIV and TB
Wednesday 10:00-11:30 |
I-26 Zhendong Chen
Plasma and cerebrospinal fluid population pharmacokinetics of vancomycin in patients with external ventricular drain
Wednesday 10:00-11:30 |
I-32 Ivan Demin
Population pharmacokinetics of LXE408 in healthy volunteers and dose predictions for adults and pediatric patients with visceral leishmaniasis
Wednesday 10:00-11:30 |
I-34 Thomas Duflot
Modelling of plasma unbound Ceftriaxone: can we improve efficacy in clinical practice ?
Wednesday 10:00-11:30 |
I-39 Aneeq Farooq
In vitro pharmacokinetic/pharmacodynamic interaction model assessing the synergy between meropenem and fosfomycin in a clinical multi-resistant K. pneumoniae isolate.
Wednesday 10:00-11:30 |
I-43 Wei Gao
Population PK/PD modeling of blood- and liver-stage activities of cabamiquine in malaria
Wednesday 10:00-11:30 |
I-45 Kamunkhwala Gausi
Bactericidal activity of pretomanid against drug-sensitive tuberculosis in the presence of rifamycins
Wednesday 10:00-11:30 |
I-54 Ibtihel Hammami
Application of Physiologically Based Pharmacokinetic Model to Predict Cobicistat Concentration during Pregnancy
Wednesday 10:00-11:30 |
I-55 Irene Hernández-Lozano
Translational pharmacokinetic-pharmacodynamic (PKPD) modelling of apramycin to facilitate prediction of efficacious dose in urinary tract infections
Wednesday 10:00-11:30 |
I-62 Felix Jost
Model-based analysis of the treatment window in passive cutaneous anaphylaxis mouse model applying an optimized study design
Wednesday 10:00-11:30 |
I-63 Piotr Juszczak
Modelling humoral immune response after a single RSV vaccination in RSV-seropositive adults aged 60 and older
Wednesday 10:00-11:30 |
I-64 Allan Kengo
Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin.
Wednesday 10:00-11:30 |
I-65 Charlotte Kern
Oral ivermectin population pharmacokinetics modeling in venous plasma in healthy study participants in Kenya in preparation of BOHEMIA cluster randomized controlled trial
Wednesday 10:00-11:30 |
I-66 Dohoon Keum
Model-based optimal dosing regimen for recombinant hepatitis B human immunoglobulin (GC1102) in Chronic Hepatitis B Patients
Wednesday 10:00-11:30 |
I-69 Simon Koele
Population pharmacokinetics of sutezolid and its main metabolite to characterize the exposure-response relationship in patients with pulmonary tuberculosis
Wednesday 10:00-11:30 |
I-72 Yu-wei Lin
Population pharmacokinetic analysis of DOVATO (DTG/3TC) as a fixed-dose combination (FDC), in antiretroviral therapy (ART)-naive HIV-1-infected adolescents, ≥12 to <18 years of age who weigh at least 25 kg
Wednesday 10:00-11:30 |
I-92 Sebastian Wicha
In vitro pharmacodynamic drug-drug interaction and translational evaluation of cabamiquine and pyronaridine as new antimalarial combination using P.falciparum field isolates
Wednesday 10:00-11:30 |
I-93 Marie Wijk
Analysis of Mycobacterium tuberculosis time to positivity in response to treatment in South African patients with drug-susceptible tuberculosis
Wednesday 10:00-11:30 |
I-94 Venkata Yellepeddi
Population Pharmacokinetics of Intermittent Vancomycin in Cystic Fibrosis Patients
Wednesday 10:00-11:30 |
I-97 Yu-Jou Lin
A pharmacometric multistate model for analyzing long-term outcomes of patients with drug-resistant tuberculosis under bedaquiline treatment
Wednesday 10:00-11:30 |
IV-06 Lu Chen
Posaconazole meta-PK analysis upon oral suspension, delayed-release tablet, and intravenous infusion in patients versus healthy volunteers: impact of clinical characteristics and race
Thursday 15:25-16:55 |
IV-19 Ryuji Kubota
Developing SARS-CoV-2 viral dynamic model in patients with COVID-19 based on amount of viral RNA and viral titer
Thursday 15:25-16:55 |
IV-21 Minji Kwon
Optimization of dosing strategy for vancomycin using a population pharmacokinetic model combined with machine learning approaches
Thursday 15:25-16:55 |
IV-24 Silvia Maria Lavezzi
Sensitivity analysis of a two-state bacterial model for prediction of clinical short-term bactericidal efficacy in tuberculosis: GSK3036656 case study
Thursday 15:25-16:55 |
IV-25 Albin Leding
Population pharmacokinetics of the antitubercular drug TBAJ587 and its two main metabolites
Thursday 15:25-16:55 |
IV-28 Giulia Lestini
Population pharmacokinetics of KAF156/LUM-SDF and exposure-response analysis for the probability of cure for patients with uncomplicated malaria
Thursday 15:25-16:55 |
IV-30 Letao Li
Population pharmacokinetics of dexamethasone in critically ill COVID-19 patients: does inflammation play a role?
Thursday 15:25-16:55 |
IV-37 Wen Yao Mak
Population pharmacokinetics and pharmacodynamics of eravacycline against pulmonary infections
Thursday 15:25-16:55 |
IV-41 Laurynas Mockeliunas
Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
Thursday 15:25-16:55 |
IV-42 Felix Müller
Identification and quantification of variability in the microdialysis technique using mixed-effects modelling within an integrated in vitro and ex vivo approach: a linezolid case study.
Thursday 15:25-16:55 |
IV-45 Jacinta Nwogu
Pemba Island, Tanzania, versus Côte d’Ivoire – Population effect on apparent clearance of active albendazole metabolites
Thursday 15:25-16:55 |
IV-46 Amaury O'Jeanson
Therapeutic drug monitoring (TDM) of β-lactam/β-lactamase inhibitor (BL/BLI) combinations: should we monitor the BLI concentration?
Thursday 15:25-16:55 |
IV-51 Elena Pascual García
Towards model-informed design of antibiotic therapies: understanding the impact of antibiotics on bacterial physiology & growth.
Thursday 15:25-16:55 |
IV-54 Anh Duc Pham
Modelling rate and extent of resistance development against colistin in Klebsiella pneumoniae and Pseudomonas aeruginosa
Thursday 15:25-16:55 |
IV-57 Veshni Pillay-Fuentes Lorente
Pemba Island, Tanzania, versus Côte d’Ivoire – Population effect on apparent clearance of active albendazole metabolites
Thursday 15:25-16:55 |
IV-58 Tim Preijers
Dosing of convalescent plasma and hyperimmune anti-SARS-CoV-2 immunoglobulins: a phase I/II dose finding study
Thursday 15:25-16:55 |
IV-63 Juan Eduardo Resendiz Galvan
Pharmacokinetics of cycloserine in an Indian population with multidrug-resistant tuberculosis.
Thursday 15:25-16:55 |
IV-70 Louis Sandra
Development of an indirect response model-based meta-analysis (MBMA) framework for the description of viral antigen decline for siRNA-based anti-HBV therapies
Thursday 15:25-16:55 |
IV-72 Maria Sanz Codina
Evaluating ceftazidime-avibactam exposure in patients undergoing automated peritoneal dialysis using population pharmacokinetic modelling
Thursday 15:25-16:55 |
IV-73 Raphaël Saporta
Translation of the in vitro antimicrobial activity of afabicin against Staphylococcus aureus to in vivo bacterial killing dynamics using a pharmacokinetic-pharmacodynamic model based on time-kill experiments
Thursday 15:25-16:55 |
IV-75 Sharon Sawe
Population pharmacokinetics of levofloxacin in South African adults treated for rifampicin-resistant tuberculosis.
Thursday 15:25-16:55 |
IV-77 Manna Semere Gebreyesus
Population pharmacokinetics of rifabutin among co-infected children on lopinavir/ritonavir-based antiretroviral therapy
Thursday 15:25-16:55 |
IV-79 Budi Octasari Susanto
Population pharmacokinetics of macozinone (PBTZ-169) and active metabolites in healthy volunteers after different oral formulations
Thursday 15:25-16:55 |
IV-84 Marinda van de Kreeke
Interspecies scaling of host inflammatory response during infection
Thursday 15:25-16:55 |
IV-86 Wisse van Os
Model-based comparison of antibiotic activity at target-site concentrations: a case study with ceftaroline and lefamulin for soft-tissue infections
Thursday 15:25-16:55 |
IV-88 Peter Velickovic
Protocol optimization for the evaluation of pharmacokinetics, biomarkers and efficacy of antitubercular drugs in a novel tuberculosis infection model in marmosets
Thursday 15:25-16:55 |
IV-89 Diego Vera-Yunca
A translational semi-mechanistic pharmacokinetic-pharmacodynamic framework to design animal studies: Application to linezolid and vancomycin
Thursday 15:25-16:55 |
IV-91 Thanakorn Vongjarudech
Optimal longitudinal QT interval correction method considering changes in heart rate variability in patients treated for drug-resistant tuberculosis
Thursday 15:25-16:55 |
